EXELDERM (sulconazole nitrate) by Journey Medical is clinical pharmacology sulconazole nitrate is an imidazole derivative with broad-spectrum antifungal activity that inhibits the growth in vitro of the common pathogenic dermatophytes including trichophyton rubrum, trichophyton mentagrophytes, epidermophyton floccosum and microsporum canis. Approved for tinea pedis (athlete's foot), tinea cruris, tinea corporis caused by trichophyton rubrum and 4 more indications. First approved in 1989.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
EXELDERM (sulconazole nitrate) is a topical imidazole antifungal cream approved in 1989 for treating dermatophyte infections including tinea pedis, tinea cruris, tinea corporis, and tinea versicolor. It works by inhibiting fungal growth in vitro against common pathogens such as Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Malassezia furfur.
Minimal commercial infrastructure with only $111K in Part D spending signals a small, legacy-stage brand team with limited growth opportunities.
CLINICAL PHARMACOLOGY Sulconazole nitrate is an imidazole derivative with broad-spectrum antifungal activity that inhibits the growth in vitro of the common pathogenic dermatophytes including Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum and Microsporum canis. It also…
Worked on EXELDERM at Journey Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on EXELDERM offers minimal career growth potential given zero linked job postings, legacy commercial status, and imminent or current generic competition. Positions are primarily in field sales and account management focused on maintaining existing market share rather than driving innovation.